- Home
- HG vs DNLI Comparison
HG vs DNLI Comparison
Compare HG & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HG
- DNLI
- Stock Information
- Founded
- HG 2013
- DNLI 2013
- Country
- HG Bermuda
- DNLI United States
- Employees
- HG N/A
- DNLI N/A
- Industry
- HG
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HG
- DNLI Health Care
- Exchange
- HG Nasdaq
- DNLI Nasdaq
- Market Cap
- HG 2.4B
- DNLI 2.1B
- IPO Year
- HG 2023
- DNLI 2017
- Fundamental
- Price
- HG $24.30
- DNLI $14.19
- Analyst Decision
- HG Buy
- DNLI Strong Buy
- Analyst Count
- HG 7
- DNLI 16
- Target Price
- HG $25.71
- DNLI $33.62
- AVG Volume (30 Days)
- HG 539.9K
- DNLI 2.0M
- Earning Date
- HG 11-05-2025
- DNLI 11-05-2025
- Dividend Yield
- HG N/A
- DNLI N/A
- EPS Growth
- HG N/A
- DNLI N/A
- EPS
- HG 3.61
- DNLI N/A
- Revenue
- HG $2,599,247,000.00
- DNLI N/A
- Revenue This Year
- HG $18.17
- DNLI N/A
- Revenue Next Year
- HG $8.74
- DNLI $802.87
- P/E Ratio
- HG $6.77
- DNLI N/A
- Revenue Growth
- HG 21.31
- DNLI N/A
- 52 Week Low
- HG $16.80
- DNLI $10.57
- 52 Week High
- HG $24.67
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- HG 58.95
- DNLI 41.95
- Support Level
- HG $23.29
- DNLI $14.63
- Resistance Level
- HG $24.67
- DNLI $15.69
- Average True Range (ATR)
- HG 0.54
- DNLI 0.68
- MACD
- HG -0.07
- DNLI -0.14
- Stochastic Oscillator
- HG 73.94
- DNLI 0.99
About HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.